Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans - PubMed (original) (raw)

Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans

M M Levine et al. J Clin Invest. 1987 Mar.

Abstract

Two Salmonella typhi mutants, 541Ty (Vi+) and 543Ty (Vi-), auxotrophic for p-aminobenzoate and adenine, were evaluated as live oral vaccines. 33 volunteers ingested single doses of 10(8), 10(9), or 10(10) vaccine organisms, while four others received two 2 X 10(9) organism doses 4 d apart. No adverse reactions were observed. Vaccine was recovered from coprocultures of 29 of 37 vaccinees (78%) and from duodenal string cultures of two; repeated blood cultures were negative. The humoral antibody response to S. typhi O, H, Vi, and lysate antigens in serum and intestinal fluid was meager. In contrast, all vaccinees manifested cell-mediated immune responses. After vaccination, 69% of vaccinees overall and 89% of recipients of doses greater than or equal to 10(9) responded to S. typhi particulate or purified O polysaccharide antigens in lymphocyte replication studies but not to antigens of other Salmonella or Escherichia coli. All individuals, postvaccination, demonstrated a significant plasma-dependent mononuclear cell inhibition of wild S. typhi.

PubMed Disclaimer

Cited by

Oral vaccination.
Dougan G, Maskell D, O'Callaghan D, Chatfield S, Charles I, Hormaeche C. Dougan G, et al. Antonie Van Leeuwenhoek. 1988;54(5):447-51. doi: 10.1007/BF00461863. Antonie Van Leeuwenhoek. 1988. PMID: 3060010 Review. No abstract available.
Human studies with synthetic peptide sporozoite vaccine (NANP)3-TT and immunization with irradiated sporozoites.
Herrington DA, Clyde DF, Davis JR, Baqar S, Murphy JR, Cortese JF, Bank RS, Nardin E, DiJohn D, Nussenzweig RS, et al. Herrington DA, et al. Bull World Health Organ. 1990;68 Suppl(Suppl):33-7. Bull World Health Organ. 1990. PMID: 2094588 Free PMC article. Clinical Trial.
Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.
Tacket CO, Hone DM, Curtiss R 3rd, Kelly SM, Losonsky G, Guers L, Harris AM, Edelman R, Levine MM. Tacket CO, et al. Infect Immun. 1992 Feb;60(2):536-41. doi: 10.1128/iai.60.2.536-541.1992. Infect Immun. 1992. PMID: 1730487 Free PMC article. Clinical Trial.
Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines.
D'Amelio R, Tagliabue A, Nencioni L, Di Addario A, Villa L, Manganaro M, Boraschi D, Le Moli S, Nisini R, Matricardi PM. D'Amelio R, et al. Infect Immun. 1988 Oct;56(10):2731-5. doi: 10.1128/iai.56.10.2731-2735.1988. Infect Immun. 1988. PMID: 3417354 Free PMC article. Clinical Trial.
Development of a nonantibiotic dominant marker for positively selecting expression plasmids in multivalent Salmonella vaccines.
McNeill HV, Sinha KA, Hormaeche CE, Lee JJ, Khan CM. McNeill HV, et al. Appl Environ Microbiol. 2000 Mar;66(3):1216-9. doi: 10.1128/AEM.66.3.1216-1219.2000. Appl Environ Microbiol. 2000. PMID: 10698796 Free PMC article.

References

1. Infect Immun. 1983 Aug;41(2):742-50 - PubMed
1. J Infect Dis. 1986 Feb;153(2):359-62 - PubMed
1. Am J Hyg. 1964 Mar;79:196-206 - PubMed
1. J Infect Dis. 1975 May;131(5):553-8 - PubMed
1. J Exp Med. 1966 Oct 1;124(4):573-83 - PubMed

Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans - PubMed (original) (raw)